ResearchMoz added Latest Research Report titled " Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance " to it's Large Report database.
The Antibacterial Drug Market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.
Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body’s immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=970729
In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.
The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 10
2.1 Disease Cluster Introduction 10
2.2 Symptoms 11
2.2.1 Pneumonia 11
2.2.2 MRSA 11
2.2.3 Sepsis 11
2.2.4 Tuberculosis 11
2.3 Diagnosis 12
2.3.1 Pneumonia 12
2.3.2 MRSA 12
2.3.3 Sepsis 12
2.3.4 Tuberculosis 12
2.4 Etiology and Pathophysiology 13
2.4.1 Pneumonia 13
2.4.2 MRSA 14
2.4.3 Sepsis 15
2.4.4 Tuberculosis 15
2.5 Epidemiology 16
2.5.1 Pneumonia 16
2.5.2 MRSA 17
2.5.3 Sepsis 17
2.5.4 Tuberculosis 18
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
The Antibacterial Drug Market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.
Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body’s immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=970729
In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.
The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 10
2.1 Disease Cluster Introduction 10
2.2 Symptoms 11
2.2.1 Pneumonia 11
2.2.2 MRSA 11
2.2.3 Sepsis 11
2.2.4 Tuberculosis 11
2.3 Diagnosis 12
2.3.1 Pneumonia 12
2.3.2 MRSA 12
2.3.3 Sepsis 12
2.3.4 Tuberculosis 12
2.4 Etiology and Pathophysiology 13
2.4.1 Pneumonia 13
2.4.2 MRSA 14
2.4.3 Sepsis 15
2.4.4 Tuberculosis 15
2.5 Epidemiology 16
2.5.1 Pneumonia 16
2.5.2 MRSA 17
2.5.3 Sepsis 17
2.5.4 Tuberculosis 18
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment